BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA

Like
Comment
Favorite

BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA

Reuters2024-11-12

Nov 12 (Reuters) - Cutia Therapeutics 2487.HK:

CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY NMPA

Further company coverage: 2487.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:52
Australian Rare Earths Ltd-Proposed Issue of Securities - Ar3
22:50
Comet Ridge Ltd - Mahalo Jv Engages Jemena for Pipeline Feed
22:50
Auking Mining Ltd-Cloncurry Project Proposed Drilling Program
22:50
Chimeric Therapeutics - US Patent Allowed for Chm Cdh17 Technology
22:44
Hyundai Steel: Plant Capacity Expected to Be 2.7 Million Tonnes Annually

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2482794181?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-12 09:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482794181","market":"us","top_or_hot":-1,"title":"BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA</title></head><body><p><span>Nov 12 (Reuters)</span><span> - </span>Cutia Therapeutics <span>2487.HK</span>:</p><ul><li><p>CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY NMPA</p></li></ul><p>Further company coverage: <span>2487.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-11-12 09:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Cutia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPA</title></head><body><p><span>Nov 12 (Reuters)</span><span> - </span>Cutia Therapeutics <span>2487.HK</span>:</p><ul><li><p>CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY NMPA</p></li></ul><p>Further company coverage: <span>2487.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nFWN3MI26Q:1","article_id":"2482794181","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482794181","pubTimestamp":1731374510,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPANov 12 (Reuters) - Cutia Therapeutics 2487.HK:CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY NMPAFurther company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Cutia Therapeutics称CU-10201（外用4%米诺环素泡沫）获得NMPA上市批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02487":0.9},"content_text":"BRIEF-Cutia Therapeutics Says CU-10201 (Topical 4% Minocycline Foam) Obtained Marketing Approval By NMPANov 12 (Reuters) - Cutia Therapeutics 2487.HK:CU-10201 (TOPICAL 4% MINOCYCLINE FOAM) OBTAINED MARKETING APPROVAL BY NMPAFurther company coverage: 2487.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}